Ascent Therapeutics

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier....

Total money raised: $8M

02142 67 Rogers Street


Phone: 617-715-1999

Updated on Mar 15, 2010
Ascent Therapeutics at CrunchBase

November, 2007

Ascent Therapeutics raised $8M in a Series A round from HealthCare Ventures, Novartis Bioventures, and TVM Capital

Ascent Therapeutics Secures $8 Million Series A